Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2021-09-16 Earnings Release
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Cantargia presenterar positiva interimsdata för kombinationsterapi med nadunolimab på ESMO-konferensen
Earnings Release Classification · 99% confidence The document is a press release ("Pressmeddelande") from Cantargia AB dated September 16, 2021. It announces the presentation of positive interim clinical data for their drug nadunolimab at the ESMO conference. The text details efficacy results (ORR, PFS) in NSCLC and PDAC patients, compares them to historical control data, discusses safety, and outlines future development plans. This content is characteristic of an initial announcement of clinical trial results, often released via a press release, which serves to inform investors about key findings before a formal, comprehensive report (like an IR or 10-K) might be filed. Since it is a direct announcement of results and not a transcript (CT), a formal annual/interim report (10-K/IR), or a presentation deck (IP), the most fitting category is 'Earnings Release' (ER) as it conveys the period's key financial/clinical performance highlights, or potentially 'Regulatory Filings' (RNS) if it were a mandatory disclosure outside of standard reporting cycles. Given the focus on presenting new clinical efficacy data, which is a major performance indicator for a biotech company, 'ER' (Earnings Release) is the closest fit for conveying key period results, even though it's clinical data rather than revenue figures. However, since the document explicitly mentions presenting data at a scientific conference (ESMO) and is a general press release about clinical progress, it functions as a high-level update. If 'ER' is strictly for financial earnings, 'RNS' (Regulatory Filings/General Announcement) is the appropriate fallback for significant, non-standardized corporate news. Given the context of biotech reporting, these clinical updates are often treated as material news announcements. I will classify it as 'RNS' as it is a general press release announcing clinical data presentation, which doesn't fit the specific financial report types (10-K, IR, ER) or presentation types (IP). H2 2021
2021-09-16 Swedish
Cantargia presents positive interim data for nadunolimab combination therapy at ESMO Congress
Earnings Release Classification · 99% confidence The document is explicitly labeled as a "Press release" announcing "positive interim data for nadunolimab combination therapy at ESMO Congress." It details clinical trial results (ORR, PFS) for NSCLC and PDAC patients, includes tables summarizing efficacy data, and concludes with contact information and a statement about regulatory obligation ("This is information that Cantargia AB is obliged to make public pursuant to the EU Market Abuse Regulation."). This format—a news announcement summarizing recent operational/clinical progress, often released outside of mandatory quarterly/annual filings—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR) or a transcript (CT), and it focuses on clinical trial updates which are key operational results, it fits best as an Earnings Release (ER) which often includes operational highlights, or RNS as a general regulatory announcement. Given the focus on presenting clinical data updates, which often accompany or substitute for quarterly earnings discussions, ER is a strong candidate. However, since it is a presentation of clinical data at a conference, and not explicitly tied to a standard quarterly reporting period (like Q3 results), RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for specific clinical/operational news releases that aren't standard financial reports or transcripts. The length (11,493 chars) is substantial, ruling out RPA based on the 'MENU VS MEAL' rule, as this is the substantive content itself, not just an announcement of attached content. FY 2021
2021-09-16 English
Cantargia: New positive interim results on nadunolimab combination therapy in NSCLC published in abstract for the annual ESMO Congress
Earnings Release Classification · 99% confidence The document is a press release dated September 13, 2021, announcing the publication of new interim clinical results for the drug nadunolimab in an abstract for the upcoming ESMO Congress. It details efficacy and safety data (ORR, DOR, PFS) from the CANFOUR study in NSCLC patients. The text explicitly states that the abstract has been published and provides context about the study and the company's pipeline. Crucially, the final paragraph states: "*This is information that Cantargia AB is obliged to make public pursuant to the EU Market Abuse Regulation.*" This structure—a brief announcement summarizing key data points and referencing an external publication (the abstract/poster presentation)—is characteristic of a general regulatory disclosure or an announcement about the release of information. Since it is not the full Annual Report (10-K), a comprehensive Interim Report (IR), or a specific financial statement, and it serves as a general market disclosure mandated by regulation (MAR), the most appropriate classification is Regulatory Filings (RNS), which acts as a general disclosure/miscellaneous filing category for such announcements that aren't covered by more specific codes like ER or DIV. It is not an Earnings Release (ER) as it focuses on clinical trial data, not period financial results. FY 2021
2021-09-13 English
Cantargia: Nya positiva interimsdata för kombinationsterapi med nadunolimab i NSCLC har publicerats i ett vetenskapligt abstrakt inför årets ESMO-konferens
Regulatory Filings Classification · 99% confidence The document is a press release dated September 13, 2021, announcing that new interim clinical data for the drug nadunolimab in NSCLC combination therapy has been published in a scientific abstract ahead of the ESMO conference. The text details clinical results (ORR, DOR, PFS) and safety profiles, and mentions that updated data will be presented at the conference. It is not a full Annual Report (10-K), a formal Audit Report (AR), or a comprehensive Interim Report (IR). It is an announcement of clinical trial results and data presentation, which falls under general investor/regulatory communication. Since it is a specific announcement about clinical trial data and publication, it is best classified as a Regulatory Filing (RNS) as it is a general disclosure required by market regulations, or potentially an Investor Presentation (IP) if it were the presentation itself, but here it is the announcement of the abstract publication. Given the context of a press release announcing the publication of abstract data for a conference presentation, RNS (Regulatory Filings) is the most appropriate general category for this type of specific, non-standard financial/operational disclosure, especially since it is not explicitly an Earnings Release (ER) or a formal Management Discussion & Analysis (MDA). The final sentence confirms it is information the company is obliged to disclose under EU market abuse regulation, strongly suggesting RNS.
2021-09-13 Swedish
Cantargia erhåller regulatoriskt godkännande att påbörja den kliniska studien CESTAFOUR med nadunolimab i kombination med cellgifter
Legal Proceedings Report Classification · 99% confidence The document is a press release ("Pressmeddelande") dated September 10, 2021, announcing that Cantargia AB has received regulatory and ethics committee approval in France to commence a new clinical Phase I/II study named CESTAFOUR for their drug nadunolimab (CAN04) across several cancer types (BTC, CRC, NSCLC). It details the study design, patient numbers, and expected timelines. This type of announcement, which communicates a significant operational/clinical milestone (regulatory approval for a trial) via a press release, is typically classified as a general Regulatory Filing (RNS) or sometimes an Investor Presentation (IP) if it were a formal deck. However, since it is a direct announcement of a regulatory event and not a comprehensive financial report (10-K, IR), a management discussion (MDA), or a specific financing event (CAP), the most appropriate general category for significant, non-financial regulatory updates that don't fit elsewhere is RNS (Regulatory Filings/General Announcement). It is not a Call Transcript (CT), Earnings Release (ER), or a formal report itself (AR, IR). Given the context of a biotech company announcing clinical trial progress and regulatory clearance, RNS is the best fit as a broad regulatory announcement.
2021-09-10 Swedish
Cantargia receives regulatory approval to start CESTAFOUR clinical study with nadunolimab in combination with chemotherapy
Legal Proceedings Report Classification · 99% confidence The document is a press release dated September 10, 2021, announcing that Cantargia AB has received regulatory approval to start a new clinical study (CESTAFOUR) for its drug nadunolimab. It details the scope of the study (indications, patient numbers, combinations) and includes standard boilerplate information about the company and its pipeline. This type of announcement, which is a specific operational update regarding clinical trials and regulatory milestones, does not fit the definitions for 10-K, ER, IR, or DEF 14A. It is not a transcript (CT), a formal audit report (AR), or a management discussion (MDA). Since it is a specific announcement about a clinical trial approval, it is best classified as a general Regulatory Filing (RNS) or potentially a Legal/Regulatory update (LTR), but RNS serves as the best general category for non-standard, time-sensitive operational news releases that don't fit the other specific categories like DIV, CAP, or MANG. Given the context of regulatory approval for a clinical trial, RNS is the most appropriate fallback for this type of press release.
2021-09-10 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.